General
Preferred name
MOCLOBEMIDE
Synonyms
Aurorix ()
Ro111163 ()
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide71320-77-9 ()
Moclobemide (Ro 111163) ()
Manerix ()
GNF-Pf-695 ()
Moclobemida ()
RO-11-1163/000 ()
Ro-111163000 ()
RO 11-1163/000 ()
Moclobemide-d4 ()
P&D ID
PD003171
CAS
71320-77-9
108375-13-9
2929883-33-8
Tags
available
drug
First approval
1990
Drug indication
Skin imperfections
Nicotine dependence
Depression
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.; Moclobemide is a substrate of CYP2C19. Although it acts as an inhibitor of CYP1A2, CYP2C19, and CYP2D6 [A3901].
ROE Moclobemide is almost completely renally excreted [L1350]. ;
DESCRIPTION Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) . It is an antidepressant and anxiolytic (antianxiety) drug. (GtoPdb)
DESCRIPTION Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 ¦ÌM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.
PRICE 29
DESCRIPTION Allosteric Akt inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Reversible MAO-A inhibitor (Tocriscreen Plus)
DESCRIPTION Moclobemide is a reversible monoamine oxidase inhibitor selective for isoform A used to treat major depressive disorder. It is used in the treatment of major depressive disorder and bipolar disorder. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants. (Enamine Bioactive Compounds)
DESCRIPTION Moclobemide (Ro111163) is a reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties. (TargetMol Bioactive Compound Library)
Compound Sets
32
AdooQ Bioactive Compound Library
A11885
Cayman Chemical Bioactives
24361
34247
ChEMBL Approved Drugs
CHEMBL86304
ChEMBL Drugs
CHEMBL86304
Concise Guide to Pharmacology 2017/18
7428
Concise Guide to Pharmacology 2021/22
7428
Concise Guide to Pharmacology 2023/24
7428
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01171
DrugBank Approved Drugs
DB01171
DrugCentral
1825
DrugCentral Approved Drugs
1825
DrugMAP
DMNZWL7
DrugMAP Approved Drugs
DMNZWL7
DrugMatrix
Enamine Bioactive Compounds
EBC-06887
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100784
Guide to Pharmacology
7428
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL86304
Mcule NIBR MoA Box Subset
MCULE-5300106938
MedChem Express Bioactive Compound Library
HY-B0534
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
moclobemide
TargetMol Bioactive Compound Library
T0084
Tocris Bioactive Compound Library
4395
Tocriscreen Plus
4395
External IDs
41
Properties
(calculated by RDKit )
Molecular Weight
268.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
1
cLogP
1.4
TPSA
41.57
Fraction CSP3
0.46
Chiral centers
0.0
Largest ring
6.0
QED
0.9
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Pathway
Metabolism
Neuroscience
Neuronal Signaling
Primary Target
Monoamine Oxidases
MOA
Inhibitor
MAO-A Inhibitors
monoamine oxidase inhibitor
Member status
member
Indication
depression, anxiety
Target
MAOA, MAOB
Monoamine Oxidase
MAO
MAO-A (5-HT)
Therapeutic Class
Antidepressants
Source data